Can we count your visit with Google Analytics? No ads, no profiles. Details
ABCL
NASDAQNext earningsNov 9todayAnalystsStrong Buy12+45%Health Care · Biotechnology
Each weekday: the watchlist of pullbacks inside uptrends, every new ticker teardown, and the bubble shifts that move names like this one. Free. Education, not advice.
Free when you join: the $HOOD Teardown Dossier (Robinhood Markets), the full desk file we sell in the shop. One per new reader.
No spam. One email per day max, unsubscribe in one click. Pro ($49/mo) includes every dossier and report in the shop.
Antibody-discovery platform - single-cell microfluidics + deep-sequencing + ML to identify and optimize antibody candidates rapidly. Canadian-listed (CAD reporting). Pipeline transition underway: from pure platform-royalty model toward direct internal candidates.
Lead ABCL635 on track for Phase 2 top-line Q3 2026. Cash position CAD 531M + CAD 124M in government funding available.
It reads our $ABCL data (thesis, key levels, peers, a year of prices) and any chart screenshot you paste, then explains the setup in plain English. Free with an email login, 5 questions a day. Education only: it never tells you to buy or sell, and it can be wrong, so check the numbers.
High-signal only
No major news in the last 7 days for ABCL - only listicles and opinion pieces, which we filter out by default. See everything anyway.
Auto-computed retracement of the trailing 52w low-high leg. Recomputed on each refresh; not a curated level.
Auto-computed retracement of the trailing 52w low-high leg. Recomputed on each refresh; not a curated level.